If you meet our eligibility requirements and do not have any health insurance, or your commercial insurance does not cover Benznidazole Tablets, product may be available free-of-charge.
If your commercial insurance does not cover or reimburse Benznidazole Tablets, you may be eligible to get your full course of therapy by paying no more than $60.
Benznidazole Tablets are a prescription medicine used to treat children 2 to 12 years of age with Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.
This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Do not take Benznidazole Tablets if you have a history of hypersensitivity reactions to benznidazole or other nitroimidazole derivatives or if you have taken disulfiram within the last two weeks. Do not consume alcoholic beverages or products containing propylene glycol for at least 3 days after therapy with Benznidazole Tablets.
Tell your healthcare professional about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Benznidazole Tablets may cause:
The risk information provided here is not comprehensive. To learn more, talk about Benznidazole Tablets with your healthcare professional or pharmacist. Before taking Benznidazole Tablets, please read the full Prescribing Information here.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Indications and Usage and Important Safety Information
Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.
This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.